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Abstract
PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DE-
SIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radio-
resistance. Inherent radiosensitivities were examined using a clonogenic survival assay. It was revealed that each
cell line differed in their response to radiotherapy. These parental breast cancer cell lines were used to establish
novel derivatives (MCF7RR, MDA-MB-231RR, and T47DRR) displaying significant resistance to ionizing radiation.
Derivative cells were compared with parental cells to identify putative biomarkers associated with the radioresis-
tant phenotype. To identify these biomarkers, complementary proteomic screening approaches were exploited
encompassing two-dimensional gel electrophoresis in combination with mass spectrometry, liquid chromatogra-
phy coupled with tandem mass spectrometry and quantitative proteomics using iTRAQ technology. RESULTS: A
large number of potential biomarkers were identified, and several of these were confirmed using Western blot
analysis. In particular, a decrease in the expression of the 26S proteasome was found in all radioresistant deriva-
tives when compared with the respective parent cells. Decreased expression of this target was also found to be
associated with radioresistant laryngeal tumors (P = .05) in a small pilot immunohistochemical study. CONCLU-
SIONS: These findings suggest that the 26S proteasome may provide a general predictive biomarker for radiother-
apy outcome.
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Introduction
Radiotherapy is a common treatment strategy used for the local con-
trol of many malignant disorders, including breast cancer, with 40%
to 60% of all cancer patients receiving radiation treatment. In addi-
tion, radiotherapy is used with potentially curative intent for some
early-stage cancers (e.g., laryngeal squamous cell carcinoma). Radio-
therapy involves the fractionated delivery of high-energy x-rays,
which exert a cytotoxic effect by producing free radicals within target
Abbreviations: ACN, acetonitrile; CI, total ion confidence score; 2DE, two-dimensional gel electrophoresis; DSBs, double-stranded DNA breaks; DTT, dithiothreitol; ER, estrogen
receptor; HRP, horseradish peroxidase; IAA, iodoacetamide; IEF, isoelectric focusing; IPG, immobilized pH gradient; LC, liquid chromatography; MA, microarray; MALDI, matrix-
assisted laser desorption/ionization; MS, mass spectrometry; MS/MS, tandem mass spectrometry; m/z, mass to charge; PR, progesterone receptor; RT-qPCR real-time quantitative
polymerase chain reaction; SDS, sodium dodecyl sulfate; SSBs, single-stranded DNA breaks; TFA, trifluoroacetic acid; TOF, time of flight
Address all correspondence to: Dr. Lynn Cawkwell, PhD, Research Laboratories, Daisy Bldg, Castle Hill Hospital, Hull, HU16 5JQ, UK. E-mail: L.Cawkwell@hull.ac.uk
1Parts of this work were funded by small grants to Mr. O. Qutob and L. Griffiths from the Peel Medical Research Trust.
2Current address: Leeds Institute of Molecular Medicine, St Jame's University Hospital, Leeds University, Leeds, UK.
Received 29 May 2009; Revised 16 July 2009; Accepted 21 July 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.09902
www.neoplasia.com
Volume 11 Number 11 November 2009 pp. 1194–1207 1194
tissues. Such radicals are the source of reactive oxygen species and
reactive nitrogen species, which create DNA damage by forming
both single-stranded DNA breaks (SSBs) and double-stranded DNA
breaks (DSBs). Cellular enzymes are able to perform the efficient re-
pair of SSBs; however, DSBs are more difficult to repair or are irrepa-
rable and thus trigger apoptosis. X-rays can also produce damage to
individual DNA bases, which increase the complexity of both SSBs
and DSBs and their subsequent repair.
Unfortunately, not all patients derive a therapeutic benefit from ra-
diotherapy because cancer cells may be refractory to treatment. This
may manifest not only as distant metastatic spread but also as disease
recurrence at the primary site. Moreover, radiotherapy is associated
with many unpleasant side effects. Some of these adverse effects are
serious and are potentially life threatening. In the curative setting,
for example in early laryngeal cancer, radiotherapy is administered in
multiple fractions during a period of several weeks, and therefore, fail-
ure to respond to a course of treatment may also delay the implemen-
tation of a more appropriate treatment strategy [1]. During this delay,
tumor progression may occur, which may impact significantly on pa-
tient survival. The identification of novel biomarkers that correlate
with radiotherapy response would not only increase our understand-
ing on the mechanisms of resistance but also allow therapy to be tai-
lored on an individual patient basis. Ultimately, those patients unlikely
to respond to radiation treatment would be spared the serious life-
threatening side effects for no therapeutic gain. Furthermore, clinicians
would be able to select the most appropriate strategy from the onset of
treatment. Such biomarkers may also provide information on new
drug targets for future therapeutic intervention such as new sensitizing
agents to increase the efficacy of radiotherapy.
Many studies have been conducted to further elucidate the mecha-
nisms of radioresistance and identify such predictive biomarkers in hu-
man cancers. For example, it has been found that the phosphoinositide-3
kinase pathway is associated with both in vivo and in vitro radioresis-
tance in several human cancers including larynx, uterine cervix, head
and neck, bladder, colon, breast, and fibrosarcoma [2–5]. In addi-
tion, the association of BCL-2 with radioresistance is well reported
[1,6]. However, the mechanisms underlying radioresistance remain
largely obscure, and it is advantageous to use global approaches to
study such complex phenomena. These techniques allow the analysis
of many targets simultaneously to obtain a comprehensive view of
complex biologic systems. This allows the expression of individual
and/or combinations of previously unknown targets to be associated
with particular disease phenotypes.
In this study, we aimed to establish novel cell line derivatives display-
ing significant radioresistance and to use global proteomic methodolo-
gies to identify proteins that may be associated with this phenotype.
Materials and Methods
Cell Lines
Breast cancer cell lines MCF7, MDA-MB-231, and T47D, repre-
senting different breast cancer subtypes, were maintained in RPMI
1640 media supplemented with 10% vol/vol fetal calf serum, 2 mM
glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. MCF7
and T47D cells represent luminal breast tumors, demonstrating estro-
gen receptor (ER)–positive and progesterone receptor (PR)–positive
phenotypes. In contrast, MDA-MB-231 cells are ER-negative, PR-
negative, and HER2-negative and represent “triple-negative,” basal-
type breast tumors.
Establishment of Novel Radioresistant Cell Line Derivatives
Novel derivatives displaying significant resistance to radiotherapy
(hereafter named MCF7RR, MDA-MB-231RR, and T47DRR) were
established from their parental breast cancer cell lines (MCF7, MDA-
MB-231, and T47D, respectively) as described below. Cells were
seeded at a concentration of 1 × 106 cells in 5 ml of supplemented
RPMI 1640 media in a screw-capped vial with a diameter of 18 mm.
Irradiation was performed at the Princess Royal Hospital, Hull, UK,
by a radiation physicist (A.W.B.) using the 6 MV beam on a linear
accelerator. A simple cradle was manufactured, which allowed the
screw-capped vial to be suspended inside a water-filled vessel (phan-
tom). The phantom used was a glass jar shaped with flat surfaces
such that the water irradiated by the x-ray beam was a simple cuboid
volume. The cradle was designed such that the screw-capped vial
containing the cells was mounted precisely at the center of the phan-
tom. Given the depth of the water between the phantom surface and
the center of the screw-capped vial (5.5 cm), the size of the irradia-
tion beam used (8 cm × 8 cm), the distance from the radiation
“source” to the center of the screw-capped vial (100 cm), and the
energy of the x-ray beam (6 MV), it was possible to calculate the ir-
radiation time required to give a specific dose to that point. It was as-
sumed that the dose given to any cells at the center of the screw-capped
vial represented that imparted to cells throughout its volume. Using
this experimental setup, it was possible to deliver consistent doses to
the cell samples throughout the course of the study. On the basis of
fractionated treatment protocols exploited within the clinic to ensure
that a degree of clinical relevance was applied to this in vitro study, each
original cell line population received a total of 40 Gy. This was admin-
istered in 20 sequential fractions of 2 Gy/wk, allowing the irradiated
cell populations a period to recover between exposures. The novel radio-
resistant derivatives (MCF7RR, MDA-MB-231RR, and T47DRR)
were established from the surviving populations of their parental breast
cancer cells (MCF7, MDA-MB-231, and T47D, respectively).
Assessment of In Vitro Response to Radiotherapy
A modified colony counting assay was used to measure the in vitro
response to ionizing radiation. Parental and derivative cells were ir-
radiated with single fractions of 0, 2, 4, 6, 8, and 10 Gy as previously
described. After irradiation, the cells from each vial were seeded at a
concentration of 1000 cells per well in triplicate wells in six-well tissue
culture plates. The cells were cultured for 12 to 14 days on which, all
media were aspirated, cell colonies were fixed with 3:1 methanol/acetic
acid, stained with 0.05% Gentian violet, and counted. A colony was
defined as a group of 50 cells or more, and plating efficiency was cal-
culated as described elsewhere [7].
Two-dimensional Gel Electrophoresis and Matrix-Assisted
Laser Desorption/Ionization Time of Flight Mass Spectrometry
Two-dimensional Gel Electrophoresis (2DE) and peptide mass finger-
printing by matrix-assisted laser desorption/ionization (MALDI) time
of flight (TOF) MS were performed as described previously [8]. Briefly,
proteins were extracted in 1 ml of isoelectric focusing (IEF) buffer
(7 M urea, 2 M thiourea, 4% CHAPS, 50 mM dithiothreitol [DTT],
1% protease inhibitor mix [80-6501-23; GE Healthcare, Bucks, UK],
0.2% 100× Bio-Lyte 3/10 Ampholyte [163-2094; Bio-Rad, Hemel
Hempstead, UK], 0.002% bromophenol blue) and quantified using
the 2D Quant Kit (80-6483-56; GE Healthcare). Samples were pre-
pared using the 2D Clean-Up Kit (163-2130; Bio-Rad) in accordance
with the manufacturer’s protocol. Separation in the first dimension was
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carried out using 11 cm pH 4 to 7 and pH 7 to 10 ReadyPrep immo-
bilized pH gradient (IPG) strips (163-2015 and 163-2019; Bio-Rad).
IPG strips were passively rehydrated in the presence of 200 μg of total
protein for 16 hours. IEF was performed using the Protean IEF Cell
(Bio-Rad) at 250 V for 20 minutes, ramped up to 8000 V for 150 min-
utes, and then maintained at 8000 V for an additional 20,000 V-h. After
equilibration, strips were transferred to the top of 11-cm Criterion gels
(345-0105; Bio-Rad) with an 8% to 16% gradient and embedded in
1% hot agarose. Electrophoresis was performed using a Criterion cell
(Bio-Rad) at 200 V for 65 minutes after which proteins were visualized
with Bio-Safe Coomassie Blue (161-0787; Bio-Rad). Three independent
gels were prepared for each cell line to account for experimental varia-
tions. Gels were digitized with a GS-800 laser densitometer (Bio-Rad),
and image analysis was performed using PDQuest (version 7.2.0; Bio-
Rad). Normalization was performed using the total quantity in valid
spots method, and the Students t-test (P < .05) was used to identify dif-
ferentially expressed proteins (at least two-fold change in expression).
Differentially expressed proteins were excised and destained using
a series of ammonium bicarbonate/acetonitrile (ACN) washing steps.
Proteins were reduced with DTT, alkylated with iodoacetamide (IAA),
and dried in a vacuum centrifuge. Gel pieces were rehydrated in 25 μl
of 40 mM ammonium bicarbonate/10% ACN containing 25 μg of
porcine methylated Trypsin Gold (V5280; Promega, Southampton,
UK) and incubated at 37°C overnight. Peptides were subsequently ex-
tracted using ACN and 5% formic acid. Peptide samples were spotted
onto an anchorchip MALDI target (Bruker Daltonics, Coventry, UK)
in a saturated matrix solution (2,5 dihydroxybenzoic acid in 50%
ACN with 1% formic acid), and mass spectra were recorded in the
reflectron mode on a Bruker Daltonics Reflex IV MALDI-TOF MS
equipped with a 337-nm nitrogen laser. Ions were accelerated through
a potential of 20 kV into the TOF mass analyzer, and ions within the
mass-to-charge (m/z) range of 900 to 2500 were detected. Data were
acquired using the Flex Control (version 2.4; Bruker Daltonics) pro-
gram and processed with Flex Analysis (version 2.4; Bruker Daltonics)
and Biotools (version 3.0; Bruker Daltonics). Peaks were deisotoped, and
monoisotopic peptide masses were assigned. Contaminating ions from
the autolysis of trypsin and keratin were removed. The resultant peptide
mass fingerprints were searched against theNCBInr database (containing
4,649,506 sequences and 1,604,431,067 residues) using the MASCOT
search engine (www.matrixscience.com) for protein identification. The
search was restricted to human taxonomy (191,507 sequences). Fixed
carbamidomethyl modifications and variable methionine oxidation
modifications were considered. A maximum of one missed tryptic cleav-
age was considered, and the mass tolerance for the monoisotopic pep-
tide masses was set at ±0.1%. Mowse scores were used to measure the
level of significance of each match, whereby scores greater than 64 were
considered a significant match (P < .05). In addition, a minimum of
25% sequence coverage was required for each significant match, and
the estimated molecular weight and pI information (from gel posi-
tioning) were compared with each match to further ensure correct iden-
tifications were assigned. Further analysis by tandem mass spectrometry
(MS/MS) was performed using the ABI 4800 PlusMALDI-TOF/TOF
analyzer (Applied Biosystems, Warrington, UK) as described later.
In-solution Digestion and Liquid Chromatographic Separation
Two hundred micrograms of total protein was precipitated using the
2D Clean-Up Kit (163-2130; Bio-Rad) and resuspended in 100 mM
ammonium bicarbonate to a final concentration of 2 mg/ml. Proteins
were reduced with DTT and alkylated with IAA. Porcine methylated
Trypsin Gold (V5280; Promega) was added at a ratio of 20:1 (wt/wt,
protein/enzyme) and incubated overnight at 37°C. The reaction was
ceased by the addition of formic acid to a final concentration of 0.1%,
and samples were dried in a vacuum centrifuge. Digested peptide mix-
tures were separated using an Ultimate 3000 Nano liquid chromatog-
raphy (LC) system (Dionex-LC Packings, Sunnyvale, CA) equipped
with a Probot Micro-fraction Collector (Dionex-LC Packings). Peptide
samples were resuspended with LC Solvent A (98% water, 2% ACN,
0.05% trifluoroacetic acid [TFA]), and 10 μg of each peptide mixture
was injected onto a C18 LC column (C18 PepMap 100, 75-μm ID;
160321; Dionex-LC Packings) for reverse phase separation. The flow
rate of the system was 0.25 μl/min, and the gradient used was as
follows: 0 to 5 minutes 2% LC Solvent B (10% water, 90% ACN,
0.05%TFA), 5 to 50minutes 2% to 30% LC Solvent B, 50 to 64min-
utes 30% to 60% LC Solvent B, 64 to 65 minutes 60% to 95% LC
Solvent B, 65 to 75minutes 95% LC Solvent B, 75 to 76minutes 95%
to 5% LC Solvent B, and 76 to 90 minutes 5% LC Solvent B. The LC
microfractions were mixed with MALDI matrix (2 mg/ml α-cyano-
4-hydroxycinnamic acid in 70% ACN and 0.1% TFA containing
10 fmol/μl Glu-Fib as an internal standard) before spotting onto an
Opti-TOF LC MALDI target plate (Applied Biosystems) with a speed
of one spot per 20 seconds. MS/MS was performed using the ABI
4800 Plus MALDI-TOF/TOF analyzer (Applied Biosystems) as de-
scribed later.
Quantitative Proteomics Using iTRAQ Technology
Two hundred micrograms of total protein was precipitated using the
2D Clean-Up Kit (163-2130; Bio-Rad) and resuspended in 500 mM
triethylammonium bicarbonate buffer with 0.1% sodium dodecyl sul-
fate (SDS) to a final concentration of 2 mg/ml. Fifty micrograms of
each sample was independently reduced using DTT, alkylated using
IAA, and digested with trypsin. Digested proteins were labeled with
iTRAQ reagents following the manufacturer’s instructions (4390812;
Applied Biosystems). Briefly, protein samples from parental cells were
labeled with iTRAQ Reagent 114, and protein samples from the radio-
resistant derivatives were labeled with iTRAQ Reagent 115. Label-
ing was allowed to proceed at room temperature for 1 hour. Labeled
samples from each cell line pair were combined, and 10 μg of each
combined sample was subjected to strong cation exchange chromatog-
raphy. Five separate fractions from each cell line pair were collected as
previously described and analyzed independently by MS/MS per-
formed using the ABI 4800 Plus MALDI-TOF/TOF analyzer (Ap-
plied Biosystems) as described later.
MS/MS
MS/MS was performed using the ABI 4800 Plus MALDI-TOF/
TOF analyzer (Applied Biosystems). Tryptic digests from 2DE analyses
were reconstituted with 50% ACN with 1% formic acid, prepared
with MALDI matrix (5 mg/ml α-cyano-4-hydroxycinnamic acid in
50% ACN with 0.1% TFA), and spotted onto an Opti-TOF 384-well
MALDI plate (Applied Biosystems).
Samples on the Opti-TOF 384-well MALDI plate and the Opti-
TOF LCMALDIplate were analyzed using an ABI 4800 PlusMALDI-
TOF/TOF analyzer (Applied Biosystems) equipped with a Nd:YAG
laser. For MS analyses, 1000 shots were accumulated per spectrum,
and ions within the m/z range of 1000 to 4000 were detected. For
MS/MS analyses, 4000 shots were accumulated per spectrumusing stop
conditions. A maximum of 10 precursors per spot were selected for
MS/MS analyses and 12 precursors per spot were selected for iTRAQ
1196 Proteomics in Radioresistance Smith et al. Neoplasia Vol. 11, No. 11, 2009
analyses; exclusion lists were created to ensure trypsin autolysis peaks,
and matrix clusters and Glu-Fib peaks (for LC-based analyses) were
not selected for sequencing. The GPS Explorer Software (Applied Bio-
systems) was used to create and search combined MS and MS/MS
ion files (for 2DE-based analyses) or MS/MS ion files (for LC-based
analyses) against theNCBInr database (containing 2,367,365 sequences
and 802,797,248 residues) using the MASCOT search engine for
peptide and protein identification. The search was restricted to human
taxonomy (129,848 sequences). Fixed carbamidomethyl modifications
and variable methionine oxidation modifications were considered. The
mass tolerance for monoisotopic peptide masses was set at ±0.1% (for
2DE-based analyses) and ±50 ppm (for LC-based analyses), and the
mass tolerance for peptide fragments was set at ±0.3 Da. A maximum
of one missed tryptic cleavage was also considered. For 2DE-based
analyses, mowse scores of greater than 64 were significant (P < .05). A
minimum of 25% sequence coverage was required for each significant
match, and the estimated molecular weight and pI information (from
gel positioning) were compared with each match to further ensure
correct protein identification. For LC-based analyses, a minimum total
ion confidence score (CI) of greater than 98% was required for pro-
tein identification.
Expression Microarray Analysis
Expression microarray (MA) slides were constructed using the Array-
Ready Human Cancer Subset v3.0 (806103; Operon, Ebersberg, Ger-
many). The subset consisted of 2876 oligonucleotides (70-mer) with
12 control housekeeping genes designed from the UniGene Database
Version Hs 147 and the Human Reference Sequence (RefSeq) Data-
base (www.ncbi.nlm.nih.gov). A QArrayMini microarray printer
equipped with 16 split-tungsten MA pins of 100 μm in diameter
(Genetix, New Milton, UK) was used to print oligonucleotides in a
triplicate random pattern onto epoxy-coated Nexterion slide E glass
microscope slides (1066643; Schott AG,Mainz, Germany). Slides were
printed at 8°C in 50% humidity and were checked for quality before
use. The full list of genes in the Human Cancer Subset v3.0 can be
viewed online (http://omad.operon.com/download/index.php). Total
RNA was extracted using the Qiagen RNeasy Mini Animal Cell
RNA Extraction Kit (74104; Qiagen, Crawley, UK) according to the
manufacturer’s protocol. RNA was quantified and assessed using the
RNA 6000 Nano Kit (5067-1511; Agilent Technologies, Stockport,
UK) and Bioanalyser (Agilent Technologies), and an RNA integrity
number of 8.5 or greater was used to select those samples of sufficient
quality for MA analysis. Expression MA analysis was performed as de-
scribed elsewhere [9]. Briefly, indirect complementary DNA (cDNA)
labeling was performed using the FairPlay II Microarray Labeling Kit
(252006; Stratagene, La Jolla, CA) using Cy3 and Cy5 monofunctional
reactive dyes (PA23001 and PA25001; Amersham Biosciences, Bucks,
UK). Labeled cDNA samples were pooled, combined with 2 μl of
1 μg/ml human Cot-1 DNA (15279011; Invitrogen, Paisley, UK), 2 μl
of 1 μg/μl Oligo d(A) (POLYA.GF; Invitrogen), 2 μl of 1 μl/μl
yeast tRNA (15401011; Invitrogen), and 390 μl of 10 mM Tris base
(pH 8.5) and concentrated to 5 μl using a Microcon YM-100 Cen-
trifugal Filter Device (42413; Millipore, Watford, UK) according to
the manufacturer’s protocol. Slides were washed once in Triton X-100
(0.1% vol/vol) for 5 minutes, twice in two separate washes of 1 mM
HCl for 2 minutes, once in 100 mM KCl solution for 10 minutes, and
finally in distilled water for 1 minute. Slides were blocked by incubating
in 1× Nexterion Blocking Solution (1066071; Schott) for 15 minutes
at 50°C, followed by rinsing in distilled water for 1 minute. Slides were
dried by centrifugation at 2200g for 2 minutes. Subsequently, a 22 ×
40-mm glass Lifterslip (22X40I-2-4710; Erie Scientific, Portsmouth,
NH) was applied to the slide over the print area. The labeled cDNA
pool (5 μl) was mixed with 1 μl of 7.5% wt/vol (0.2% final concentra-
tion) BSA (15260037; Invitrogen) and 19 μl of Nexterion Hybridisation
Buffer E (1066075; Schott) to make a total hybridization volume of
25 μl. The hybridization mix was denatured at 95°C for 3 minutes in
a thermal cycler before application to the MA slide. Slides were sealed
into humidified array hybridization chambers (4120-000002; MWG-
Biotech, Ebersberg, Germany) and incubated at 65°C for 16 to 18 hours
in a dark hybridization oven. The coverslip was subsequently removed
by gentle agitation in 0.2-μm filtered 4× SSC. Slides were washed for
5 minutes in filtered 2× SSC/0.1% wt/vol SDS. Slides were dipped in
filtered 2× SSC to remove residual SDS and then washed for 5 minutes
in filtered 2× SSC. Finally, slides were dipped in filtered 0.2× SSC and
washed for 5 minutes in filtered 0.2× SSC. Slides were dried by cen-
trifugation at 2200g for 2 minutes. Images were acquired using the
GenePix 4100A Personal Microarray Scanner in combination with
Genepix Pro (version 4.1) image collection software (Molecular De-
vices Corporation, Sunnyvale, CA). The MA slides were scanned at a
resolution of 5 μm per pixel with the photomultiplier tube gains
manually set for each dye to ensure a normal ratio across the whole
array of 1 (±0.1). After application of the .gal file, the results files were
imported into Acuity v4.0 (Molecular Devices Corporation) and nor-
malized using the nonlinear Lowess normalization method. A data
set was created by filtering each array to include only those features with
the parameter “Flags ≥ 0.” This ensured that only those features that
were “found” and not “bad” or “not found” were included in the analy-
ses. Once filtered, the data were analyzed according to the following
parameters: low interarray variance (P ≤ .05) and absolute log (635/
532) value ≥1.0/−1.0 in three of four independent experiments. A log
ratio value of ≥1.0/−1.0 was chosen for the cutoff level because this rep-
resented an actual fold change of two-fold or greater, which is a standard
for MA analysis [10].
Real-time Quantitative Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction (RT-qPCR) was
performed as described elsewhere [9]. Briefly, 2 μg of total RNA were
treated with 2 U of amplification grade DNase 1 (AMP-D1; Sigma-
Aldrich, Poole, UK) at room temperature for 15 minutes and then
reverse-transcribed into cDNA using the iScript cDNA Synthesis Kit
(170-8890; Bio-Rad). RT-qPCR was carried out with 50 ng of equiv-
alent RNA template using the AB Power SYBR Green Supermix
(4367659; Applied Biosystems) in a 20-μl reaction volume on a MyiQ
Single-Color Real-time PCR Detection System (Bio-Rad). Primer
details are shown in Table 1 and synthesized by Applied Biosystems.
Data were collected using the MyiQ Optical System Software (Bio-
Rad), and data analysis was carried out according to the method of
Pfaffl [11].
Western Blot Analysis
Proteins were extracted in 1 ml of Laemmli buffer (62.5 mM Tris-
HCl [pH 6.8], 10% glycerol, 2% SDS, 5% β-mercaptoethanol, 1%
protease inhibitor mix, 0.00125% bromophenol blue) and quanti-
fied using the RC-DC Protein Assay Kit (500-0122; Bio-Rad). Equal
amounts of protein (15-25 μg per lane) were loaded onto a 12% ho-
mogenous NuPage gel (EC6005BOX; Invitrogen). Electrophoresis
was performed at 200 V for 60 minutes, and proteins were transferred
to a 0.45-μmnitrocellulose membrane (162-0115; Bio-Rad) at 400mA
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for 60 minutes at 4°C. Membranes were incubated in blocking buffer
(5% nonfat dry milk, 0.05% Tween 20 in Tris-buffered saline [TBS])
for 60 minutes. Aldolase A (1:200; SC-30082; Santa Cruz Biotech-
nology, Santa Cruz, CA), aspartyl-tRNA synthetase (DARS, 1:1000;
H00001615-M01; Abnova Corporation, Taipei City, Taiwan), glucose-
regulated protein/GRP78 (1:400; ab21685; Abcam, Cambridge, UK),
GSTM3 (1:2000; kindly provided by Professor John Hayes, Biomedical
Research Centre, University of Dundee, UK), HSP90 Beta (1:100; 37-
9400; Zymed, Paisley, UK), keratin 17 (1:50; ab2502; Abcam), moesin
(1:200; SC-13122; Santa Cruz Biotechnology), p53 (1:200; 554293;
BD Pharmingen, Oxford, UK), L-plastin (1:100; MS-1326; Neomark-
ers, Loughborough, UK), 26S proteasome (1:100; ab21165; Abcam),
proteasome alpha 7 subunit/PSMA7 (1:200;H00005688-M01; Abnova
Corporation), QARS (1:500; H00005859-M01; Abnova Corporation),
triosephosphate isomerase 1 (1:1000; H00007167-M02A; Abnova Cor-
poration), TRAP1/HSP75 (1:100;MS-1309;Neomarkers), E1 ubiquitin
activating enzyme (1:5000; ab24623; Abcam), or the glyceraldehyde
3 phosphate dehydrogenase (GAPDH) loading control (1:10,000;
ab9485; Abcam) were added for 2 hours at room temperature. The
appropriate horseradish peroxidase (HRP)–conjugated secondary anti-
body (antimouse or antirabbit; SC-2031 or SC-2030; Santa Cruz Bio-
technology) was then incubated with themembrane for 1 hour. Proteins
were detected using the SuperSignal West Pico Chemiluminescence
Substrate (PN34078; Pierce, Loughborough, UK) according to the
manufacturer’s protocol. Films were scanned using a GS-800 laser den-
sitometer, and protein expression was measured using Quantity One
software (version 4.6.1; Bio-Rad).
Immunohistochemistry
Local research ethics committee approval was obtained for the col-
lection of clinical data and archival pretreatment biopsy material. Pa-
tients whose conditions were diagnosed with early-stage (T1-T2 N0)
laryngeal cancer and treated with single-modality radiotherapy with
curative intent (55-60 Gy in 20-25 fractions) were identified from data-
bases held in ENT departments in England [1]. Patients were identi-
fied as having radiosensitive or radioresistant tumors according to their
response to radiotherapy. The radiosensitive and radioresistant groups
were matched with regards to T stage, laryngeal subsite, and smoking
history to reduce confounding variables. Tumors were staged according
to the TNM classification and were all clinically nodal negative (N0)
and metastatic negative (M0) at the time of treatment.
The radiosensitive group of tumors consisted of pretreatment biop-
sies from 22 patients. The criteria for a radiosensitive tumor were as
follows: 1) the radiotherapy had to have been given as a single-modality
treatment with curative intent for a biopsy-proven squamous cell
carcinoma of the larynx; 2) after treatment, patients had a minimum
follow-up of 3 years with no evidence of a recurrent laryngeal tumor.
The radioresistant group of tumors consisted of pretreatment biop-
sies from 22 patients. The criteria for a radioresistant tumor were
as follows: 1) the radiotherapy had to have been given as a single-
modality treatment with curative intent for a biopsy-proven squamous
cell carcinoma of the larynx; 2) biopsy-proven recurrent squamous cell
carcinoma, the recurrence occurring at the original anatomical site
within 12 months of finishing a course of radiotherapy.
Immunohistochemical assays were carried out as described pre-
viously [12]. Briefly, 4 μm sections were cut onto Superfrost Plus
microscope slides (Menzel-Glaser, Braunschweig, Germany) and
incubated at 37°C overnight. Sections were dewaxed in Histoclear
(National Diagnostics, Hull, UK) and rehydrated in alcohol before
blocking endogenous peroxidase by incubating in 400 ml of metha-
nol containing 8 ml of hydrogen peroxide (30% vol/vol). Antigenic
sites were retrieved by boiling slides in 1500 ml of distilled water with
15 ml of Antigen Unmasking Solution (H-3300; Vector Laboratories,
Peterborough, UK) in a pressure cooker for 3 minutes at 15 psi. Non-
specific protein was blocked with 1× casein (SP-5020; Vector Labora-
tories) diluted in TBS for 10 minutes, and endogenous avidin and
biotin were blocked by 15-minute incubation periods with biotin
and avidin, respectively (Avidin Biotin Blocking Kit; SP-2001; Vec-
tor Laboratories). The 26S proteasome primary antibody (ab21165;
Abcam), as used for Western blot analysis, was prepared to a dilution
of 1:50 with 0.2× casein in TBS and applied at room temperature
for 2 hours. A negative control was also included, in which the pri-
mary antibody was omitted. Antibody detection was carried out using
an HRP-conjugated Streptavidin-Biotin Complex Duet Kit (K0492;
DakoCytomation, Ely, UK) according to the manufacturer’s protocol.
Immunoreactivity was visualized using 0.05% 3′,3-diaminobenzidine
as the chromogen, and 0.01% hydrogen peroxide was used as the
HRP substrate. Sections were counterstained with Harris hematoxylin,
dehydrated in alcohol, and mounted with Histomount (National Diag-
nostics). Slides were scored by two independent investigators, and any
discrepancies in the results were resolved by consensus following re-
assessment by both investigators. Sections were scored as negative if
expression of the 26S proteasome was lost in more than 50% of the
tumor cells. This is because loss of expression was considered as detri-
mental. Association between protein expression and response to radio-
therapy was determined using the χ 2 test using SPSS (version 14, SPSS
Inc, Chicago, IL).
Results
Inherent Sensitivity of Parental Cell Lines to Radiotherapy
Figure 1 demonstrates the relative sensitivity of each of the parent
human breast cancer cell lines MCF7, MDA-MB-231, and T47D,
to ionizing radiation given as single fractions over the dose range of
0 to 10 Gy. The three cell lines had plating efficiencies of 30.9 ±
Table 1. Primers Used Successfully for RT-qPCR.
Gene Sense Primer Antisense Primer Amplicon Length (bp)
ER 5′-GGAGGGCAGGGGTGAA-3′ 5′-GGCCAGGCTGTTCTTCTTAG-3′ 100
GAPDH 5′-CATCTTCCAGGAGCGAGATCC-3′ 5′-GTGGTGAAGACGCCAGTGG-3′ 87
GSTM3 5′-GCGATACTGGCATTTCCCTA-3′ 5′-TCTCCAACTGTGCAATCTCG-3′ 104
PGR 5′-CGCGCTCTACCCTGCACTC-3′ 5′-TGAATCCGGCCTCAGGTAGTT-3′ 121
PSME1 5′-GTGGATGTGTTTCGTGAAGACC-3′ 5′-CTTGGGGAAATAGCTCCCGAG-3′ 66
PSME2 5′-GCAAACAGGTGGAGGTCTTCAGG-3′ 5′-CATTACATGAGTCTCCTTGGAGG-3′ 515
Sequences were selected using RTPrimerDB (http://medgen.ugent.be/rtprimerdb/) or PrimerBank (http://pga.mgh.harvard.edu/primerbank/). The sequences for PSME2 were previously used by
Maksymowych et al. [33]. GAPDH was used as the reference gene.
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4.16%, 11 ± 0.47%, and 13.5 ± 0.40%, respectively. There was no
significant difference in cell survival between the three parent cell
lines based on the survival fraction at 2 Gy. When the survival frac-
tion at 4 Gy was calculated, there was a significant difference be-
tween survival of MCF7 versus MDA-MB-231 and MCF7 versus
T47D (P < .05 by ANOVA). MDA-MB-231 demonstrated the most
inherent radioresistance of the three parent cell lines.
Establishment of Radioresistant Derivatives
The three parental breast cancer cell lines (MCF7, MDA-MB-
231, and T47D) were subjected to fractionated radiotherapy to a
total dose of 40 Gy, and the novel radioresistant derivatives (hereafter
named MCF7RR, MDA-MB-231RR, and T47DRR, respectively)
were assayed using the modified colony counting assay (Figure 1).
The MCF7RR and T47DRR cell lines were significantly more resis-
tant to radiotherapy than their parent cell lines (MCF7 and T47D,
respectively) at 4, 6, 8, and 10 Gy (P ≤ .01; ANOVA) with maximal
37-fold and 34-fold increases, respectively, in resistance observed at
8 Gy. The MDA-MB-231RR cell line was significantly more resis-
tant than its MDA-MB-231 parent at 6, 8, and 10 Gy (P ≤ .01;
ANOVA) with a maximal 22-fold increase in resistance observed at
8 Gy. Western blot analysis revealed that parent and derivative cells
demonstrated similar expression levels of p53. Similarly, RT-qPCR
analysis revealed that both MCF7 and T47D cells retained their
ER- and PR-positive status following treatment. RT-qPCR analysis
was also able to detect only trace amounts of ER and PR messenger
RNA (mRNA) in MDA-MB-231 cells both before and after treat-
ment, indicating that treatment with radiotherapy had not altered
the phenotypic characterization of these cell lines.
2DE/MS Analysis
The protein profiles of three parental breast cancer cell lines
(MCF7, MDA-MB-231, and T47D) were compared with the pro-
tein profiles of their novel radioresistant derivatives (MCF7RR,
MDA-MB-231RR, and T47DRR, respectively) using 2DE. Proteins
were fractionated using medium–pH range IPG strips (pH 4-7 and
pH 7-10) to maximize resolution. A representative gel image is shown
in Figure 2. In total, a significant change in the expression of 65 pro-
teins (down-regulation of 25; up-regulation of 40) was detected in one
or more of the radioresistant derivatives. The expression of 18 proteins
(16 proteins in the pH 4-7 range and 2 proteins in the pH 7-10 range;
12 downregulated proteins and 6 upregulated proteins) was signifi-
cantly altered in the MCF7RR cell line compared with the MCF7
parental cell line. The expression of 18 proteins (14 proteins in the
pH 4-7 range and 4 proteins in the pH 7-10 range; 9 downregulated
proteins and 9 upregulated proteins) was significantly altered in the
MDA-MB-231RR cell line compared with the MDA-MB-231 paren-
tal cell line. The expression of 29 proteins (23 proteins in the pH 4-7
Figure 1. A log-linear plot demonstrating the relative sensitivity of
the three parental breast cancer cell lines (MCF7, MDA-MB-231,
and T47D) and their novel radioresistant derivatives (MCF7RR,
MDA-MB-231RR, and T47DRR, respectively) to ionizing radiation
over the range of 0 to 10 Gy as determined by a modified colony
counting assay. Each point represents the mean of six replicates
over two independent experiments. Compared with the respective
parental cells, MCF7RR and T47DRR demonstrated a significant
increase in survival at 4, 6, 8, and 10 Gy (P ≤ .01; ANOVA). MDA-
MB-231RR cells demonstrated a significant increase in survival at 6,
8 and 10 Gy compared with parental MDA-MB-231 cells (P ≤ .01;
ANOVA). Compared with the respective parental cells, the overall
maximum resistance demonstrated by MCF7RR, MDA-MB-
231RR, and T47DRR was 37-fold, 22-fold, and 34-fold, respectively,
all of which where observed at 8 Gy (P ≤ .01; ANOVA).
Figure 2. Representative 2D gaussian patterns for the MCF7 (upper
panel) and MCF7RR (lower panel) cell lines in the pH range of 4 to 7.
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range and 6 proteins in the pH 7-10 range; 4 downregulated proteins
and 25 upregulated proteins) was significantly altered in the T47DRR
cell line compared with the T47D parental cell line. Figure 3 shows
several examples of differentially expressed proteins from the analysis of
each cell line pair. A total of 65 protein spots were excised and sub-
jected to tryptic digestion. The resulting peptides were extracted and
analyzed by MALDI-TOF and/or MALDI-TOF/TOF MS. Assign-
ments were made for 50 of these 65 protein spots (Table 2). After clas-
sification according to their function, many of these proteins played a
role in metabolism, protein biosynthesis, or the ubiquitin-proteasome
protein degradation pathway (Table 2).
LC-MS/MS Analysis
LC-MS/MS was used as a complementary approach to 2DE-MS
for the analysis of all proteins present in T47D and T47DRR cells. A
total of 586 and 652 proteins were identified in T47D and T47DRR
cells, respectively, using a minimum CI score of greater than 98%.
Those proteins identified in both cell lines and any redundant entries
were removed to reveal those proteins, which were unique to each
cell sample. In total, 242 unique proteins were identified in T47D
cells (that could not be identified in T47DRR cells) with MASCOT
ion scores ranking from 556 to 37. Forty of these proteins were “un-
known,” “unnamed,” “hypothetical,” or “predicted.” Likewise, a total
of 310 unique proteins were identified in T47DRR cells (that could
not be identified in T47D cells) with MASCOT ion scores ranking
from 757 to 37. Seventy-five of these proteins were “unknown,” “un-
named,” “hypothetical,” or “predicted.” The proteins from each cell
line were categorized into functional groups, and several changes
were observed between cell lines. Of note, several proteins involved
in the ubiquitin-proteasome degradation pathway were missing in
T47DRR cells compared with parental cells (Table 3). This is in ac-
cordance with our 2DE-MS results, which also identified the down-
regulation of several proteasome-associated proteins (Table 2).
Quantitative Proteomics
A complementary quantitative approach for the identification of
biomarkers associated with radioresistance in this panel of novel
breast cancer cell lines was performed using iTRAQ technology. A
minimum CI of greater than 98% was used for the identification
of proteins, and at least two peptide sequences were matched to most
identified proteins. A total of 1370 proteins were identified in the
analysis of the MCF7/MCF7RR cell line pair with MASCOT ion
scores ranking from 2717 to 39. Likewise, 1025 proteins were iden-
tified in the MDA-MB-231/MDA-MB-231RR cell line pair with
MASCOT ion scores ranking from 2336 to 39. Finally, 1252 proteins
were identified in the T47D/T47DRR cell line pair with MASCOT
ion scores ranking from 3320 to 39. Using a standard two-fold change
or greater in expression, these iTRAQ analyses revealed significant
changes in the expression of 40 characterized proteins in one or more
of the radioresistant derivatives (Table 4). In the MCF7RR cell line,
relative to the MCF7 parent, 23 proteins demonstrated a decrease in
expression (ranging from 2.0- to 6.2-fold change) and 5 proteins dem-
onstrated an increase in expression (ranging from 2.0- to 3.0-fold
change). In the MDA-MB-231RR cell line, relative to the MDA-
MB-231 parent, seven proteins demonstrated a decrease in expression
(ranging from 2.0- to 3.5-fold change). In the T47DRR cell line, rel-
ative to the T47D parent, four proteins demonstrated a decrease in
expression (ranging from 2.0- to 2.5-fold change) and one protein
demonstrated an increase in expression (2.4-fold change). A decrease
in the expression of glucose-regulated protein (GRP78) and filamin A
alpha was found in both MCF7RR and MDA-MB-231RR cells in re-
lation to their parental cells (MCF7 and MDA-MB-231, respectively).
Figure 3. Representative 2DE gel analysis showing several examples of proteins identified by mass spectrometry (Table 2) that were
differentially expressed (at least two-fold) between the radioresistant derivatives (MCF7RR, MDA-MB-231RR, and T47DRR) and their
parental cell lines (MCF7, MDA-MB-231, and T47D, respectively). The histograms show relative spot quantities; the first three bars
represent the quantity of that spot in each of the three parental biologic replicates and the last three bars represent the quantity of that
spot in each of the three radioresistant biologic replicates. Spots were significantly differentially expressed as determined by the Stu-
dent’s t test (P < .05) and were all tested by Western blot analysis (Figure 4). GST-M3 indicates glutathione-S -transferase mu-3; PSMA7,
proteosome alpha 7 subunit; TRAP1, TNF receptor-associated protein-1/HSP75.
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Expression MA Analysis
A targeted expression MA screening approach was used for the
complementary analysis of the MCF7 and MCF7RR cell lines. This
analysis independently confirmed the decrease in expression of GSTM3
(by 3.6-fold) and PSME1 (by 2.8-fold) in the MCF7RR cells, which
had been identified by the 2DE-MS analysis of these cells. RT-qPCR
was used to confirm the expression MA data and revealed a 3.8-fold
decrease in the expression of GSTM3 and a 2.7-fold decrease in the
expression of PSME1 in MCF7RR cells relative to parental cells
(Table 5). In addition, PSME2, a related target also identified by
2DE-MS, was selected for analysis by RT-qPCR analysis and exhibited
a 2.0-fold decrease in the expression in MCF7RR cells relative to pa-
rental cells (Table 5).
Western Blot Analysis
To validate the proteomics data, several targets were selected for
confirmation by Western blot analysis. Each band was normalized
to GAPDH, and protein expression was quantitated using densito-
metric analysis. Because α-tubulin was identified as a differentially
expressed protein in the 2DE-MS study, GAPDH was selected
as the loading control after equal expression of this protein was ob-
served between cell line pairs after careful protein quantification and
Table 2. Proteomics Data, Ranked by Mowse Score, for All Assigned Proteins Associated with In Vitro Radioresistance in MCF7RR, T47DRR, and MDA-MB-231RR Cells Identified Using 2DE in
Combination with MALDI-TOF or MALDI-TOF/TOF MS.
Protein NCBI Accession Gene Name Known/Proposed Function RR Cell Line pH Gradient Expression Level Mowse Score
Heat shock 90-kDa protein 1 beta*,† 34304590 HSP90AB1 Protein folding/degradation T47D 4-7 ▴ 787
Eukaryotic translation initiation factor 4A, isoform 1*,‡ 54696624 EIF4A1 Protein biosynthesis T47D 4-7 ▴ 725
Ubiquitin activating enzyme E1*,†,‡ 35830 UBA1 Ubiquitin cycle T47D 4-7 ▴ 492
α-Tubulin* 37492 TUBA1A Structural T47D 4-7 ▾ 473
Glutaminyl-tRNA synthetase*,† 4826960 QARS Protein biosynthesis MDA 7-10 ▴ 309
TRAP1*,† 3273383 TRAP1/HSP75 Protein folding/degradation T47D 4-7 ▴ 302
G elongation factor, mitochondrial 1* 18390331 GFM1 Protein biosynthesis T47D 4-7 ▴ 177
Triosephosphate isomerase 1*,† 17389815 TPI1 Metabolism MDA 7-10 ▾ 177
Lymphocyte cytosolic protein 1 (L-plastin)† 14043359 LCP1 Structural MCF7 4-7 ▾ 155
Mitochondrial malate dehydrogenase precursor‡ 21735621 MDH2 Metabolism T47D 7-10 ▴ 149
Hypothetical (PGM2) 12052930 PGM2 Metabolism MDA 4-7 ▾ 149
HSPC263 6841176 OTUB1 Ubiquitin cycle T47D 4-7 ▴ 148
Vinculin isoform VCL 4507877 VCL Cell adhesion T47D 4-7 ▴ 144
Actinin, alpha 4 12025678 ACTN4 Structural MCF7 4-7 ▴ 133
Eukaryotic translation elongation factor 2 4503483 EEF2 Protein biosynthesis T47D 4-7 ▴ 133
Solute carrier family 25, member 24 46249805 SLC25A24 Transport MDA 4-7 ▴ 131
Fructose-bisphosphate aldolase A† 4557305 ALDOA Metabolism T47D 7-10 ▴ 125
Proteasome subunit, alpha type, 7*,† 30583169 PSMA7 Protein degradation MDA 7-10 ▾ 124
Voltage-dependent anion channel 1 4507879 VDAC1 Transport T47D 7-10 ▴ 121
Aspartyl-tRNA synthetase† 179102 DARS Protein biosynthesis T47D 4-7 ▴ 118
Aspartyl-tRNA synthetase† 62896511 MDA ▾ 95
Glutathione S -transferase M3†,§ 14250650 GSTM3 Metabolism MCF7 4-7 ▾ 118
Keratin 17† 48735384 KRT17 Structural MCF7 4-7 ▾ 117
Pyrophosphatase 1 85397510 PPA1 Metabolism MCF7 4-7 ▾ 115
Moesin† 4505257 MSN Structural MDA 4-7 ▾ 108
Leucine-rich PPR motif-containing protein 31621305 LRPPRC Transport MCF7 4-7 ▴ 108
N -Acetyltransferase ARD1 10835057 ARD1A Protein modification MCF7 4-7 ▾ 105
Proteasome activator subunit 2 (PA28 beta)§ 13325110 PSME2 Protein degradation MCF7 4-7 ▾ 105
Glyoxalase domain containing 4 16198390 GLOD4 Unknown MCF7 4-7 ▾ 101
EPB41 24657823 EPB41 Structural MDA 4-7 ▾ 101
Proteasome subunit, alpha type, 2* 51094758 PSMA2 Protein degradation MDA 7-10 ▾ 101
Spermidine synthase 63253298 SRM Spermidine biosynthesis MDA 4-7 ▾ 99
Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 4504447 HNRNPA2B1 mRNA processing T47D 7-10 ▾ 96
ER lipid raft associated 2 isoform 1 6005721 ERLIN2 Unknown T47D 4-7 ▴ 95
STARD10 31455229 STARD10 Unknown MCF7 4-7 ▾ 95
S -Adenosylhomocysteine hydrolase 9951915 AHCY Metabolism T47D 4-7 ▴ 94
Isocitrate dehydrogenase 3 (NAD+), alpha precursor 5031777 IDH3A Metabolism MDA 4-7 ▴ 91
Ribosomal protein, large, P0 12654583 RPLP0 Protein biosynthesis MCF7 4-7 ▾ 90
Enoyl coenzyme A hydratase, short chain, 1, mitochondrial 14286220 ECHS1 Metabolism MDA 4-7 ▴ 88
Eukaryotic translation initiation factor 3, subunit 2 beta 54696064 EIF3I Protein biosynthesis MCF7 4-7 ▾ 82
Proteasome activator subunit 1 isoform 2§ 30581141 PSME1 Protein degradation MCF7 4-7 ▾ 81
Growth inhibiting gene 5 protein 41350397 CACYBP Ubiquitin cycle MCF7 7-10 ▾ 81
Mitochondrial aldehyde dehydrogenase 2 precursor 25777732 ALDH2 Metabolism MDA 4-7 ▴ 80
Pro-alpha 1 (II) collagen 30097 COL2A1 Structural MDA 4-7 ▾ 75
CNDP dipeptidase 2 (metallopeptidase M20 family),
isoform CRA_e
119586960 CNDP2 Peptidolysis MDA 4-7 ▴ 72
Hypothetical protein LOC80007 13376421 C10orf88 ATPase activity MDA 4-7 ▴ 70
Lysyl-tRNA synthetase 11095909 KARS Protein biosynthesis MCF7 4-7 ▴ 69
Expression levels represent the up- (▴) or down- (▾) regulation of proteins by at least two-fold in the radioresistant derivatives relative to parental cells. Gene ontology information was derived from the
GOA database (http://www.ebi.ac.uk/GOA/).
A summary of all confirmed data is shown in Table 5.
*Proteins for which MS/MS data were obtained.
†Targets selected for Western blot analysis (Figure 4).
‡Proteins identified in two separate but closely mapped spots on the same gel.
§Targets selected for analysis by RT-qPCR.
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equal lane loading. Fold changes were calculated using the normal-
ized quantities from three biologic replicates for each cell line.
Several targets identified by 2DE-MS from each cell line pair were
selected for Western blot analysis (Table 2), and confirmation of sig-
nificant (at least two-fold) differential protein expression was estab-
lished for a number of targets (Figure 4; Table 5).
From the iTRAQ analysis, glucose-regulated protein (GRP78) was
selected for Western blot analysis because this protein was identified
from two radioresistant cell lines. A significant decrease in expression
of this protein was observed in MCF7RR cells (2.9-fold decrease)
and MDA-MB-231RR cells (2.0-fold decrease), thereby confirming
this iTRAQ result (Figure 5; Table 5).
The 26S Proteasome
Data obtained for all cell lines demonstrated a trend for decreased
expression of protein components from the 26S proteasome in radio-
resistant cells. Results from the 2DE analyses indicated that a decrease
in the expression of proteasome subunit alpha type 2 (PSMA2) and
proteasome subunit alpha type 7 (PSMA7) was associated with radio-
resistance (Table 5). Furthermore, the LC-MALDI MS/MS analysis of
Table 3. Proteins Associated with the Ubiquitin-Proteasome Pathway of Protein Degradation Which Were Identified in T47D Parent Cells But Not in T47DRR Cells Using LC-MALDI-TOF/TOF MS.
Protein NCBI Accession Gene Known/Proposed Function Total Ion Score Total Ion CI (%)
Proteasome alpha 1 subunit, isoform 2 16307002 PSMA1 Protein degradation 80 100
26S proteasome subunit p40.5 3618343 PSMD13 Protein degradation 65 99.997
Proteasome (prosome, macropain) subunit, beta type, 2 30583113 PSMB2 Protein degradation 41 99.322
Ubiquitin-associated protein 2–like 13111995 UBAP2L Ubiquitin cycle 100 100
Hyd protein (ubiquitin protein ligase E3 component n-recognin 5 9545980 UBR5 Ubiquitin cycle 44 99.626
Table 4. Proteomics Data, Ranked by Fold Change, for All Differentially Expressed (at Least Two-Fold) Characterized Proteins Associated with Radioresistance in One or More of the Radioresistant
Derivatives Identified Using iTRAQ Technology.








Keratin 8 49256423 KRT8 Structural MCF7 2717 100.0 0.161 ▾6.2
Keratin 19 6729681 KRT19 Structural MCF7 2387 100.0 0.278 ▾3.6
Vimentin 7576229 VIM Structural MDA 2336 100.0 0.288 ▾3.5
Glucose-regulated protein (GRP78)* 6900104 HSPA5 Regulation of apoptosis MCF7 2241 100.0 0.304 ▾3.3
MDA 1882 100.0 0.491 ▾2.0
Heat shock 70-kDa protein 1A 55962551 HSPA1A Protein folding MCF7 2183 100.0 0.315 ▾3.2
Cytokeratin 18 (424 AA) 30311 KRT18 Structural MCF7 2183 100.0 0.327 ▾3.1
ACSF3 protein 47938904 ACSF3 Unknown MCF7 39 98.02 3.0 ▴3.0
Heat shock protein 90-alpha 72219 HSP90AA1 Protein folding MCF7 2161 100.0 0.349 ▾2.9
Plectin 1 isoform 3 41322908 PLEC1 Structural MDA 2118 100.0 0.352 ▾2.8
Filamin A, alpha (actin binding protein 280) 57284201 FLNA Structural MCF7 2088 100.0 0.353 ▾2.8
Filamin A, alpha (actin binding protein 280) 57284203 MDA 2094 100.0 0.371 ▾2.7
Nucleolin 55956788 NCL Angiogenesis MCF7 1895 100.0 0.371 ▾2.7
Heat shock 70-kDa protein 9 precursor 24234688 HSPA9 Protein folding MCF7 1824 100.0 0.402 ▾2.5
Structural maintenance of chromosomes 3 28958118 SMC3 Cell Division T47D 60 99.98 0.403 ▾2.5
Desmoyokin 627367 AHNAK Nervous system development MDA 2014 100.0 0.417 ▾2.4
OS9 17986213 OS9 Unknown T47D 97 100.0 0.418 ▾2.4
Fatty acid synthase 41872631 FASN Metabolism MCF7 1774 100.0 0.420 ▾2.4
PRKC, apoptosis, WT1, regulator 55769533 PAWR Regulation of transcription T47D 51 99.88 2.4 ▴2.4
Lamin A/C transcript variant 1 57014043 LMNA Structural MCF7 1652 100.0 0.429 ▾2.3
Prolyl 4-hydroxylase, beta polypeptide 48735337 P4HB Protein folding MCF7 1650 100.0 0.432 ▾2.3
MYH9 47678583 MYH9 Structural MDA 1955 100.0 0.442 ▾2.3
Mitochondrial ATP synthase beta subunit precursor 32189394 ATP5B Transport MCF7 1626 100.0 0.444 ▾2.3
Chaperonin 60, Hsp60 6996447 HSPD1 Protein folding MCF7 1567 100.0 0.444 ▾2.3
Surfeit 1 55958186 SURF1 Unknown T47D 56 99.96 0.445 ▾2.2
Heat shock protein 90-kDa beta (Grp94), member 1 44890631 HSP90B1 Protein folding MCF7 1556 100.0 0.449 ▾2.2
Cytokeratin 1419564 KRT8 Structural MCF7 1443 100.0 0.450 ▾2.2
ACTB protein 15277503 ACTB Structural MCF7 1440 100.0 0.458 ▾2.2
Heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 14043072 HNRNPA2B1 mRNA processing MCF7 1350 100.0 0.462 ▾2.2
Pyruvate kinase, muscle 31416989 PKM2 Metabolism MCF7 1322 100.0 0.467 ▾2.1
ER-60 protein 2245365 PDIA3 Transport MCF7 1315 100.0 0.469 ▾2.1
Aldolase A 49456715 ALDOA Metabolism MCF7 1242 100.0 0.479 ▾2.1
Protein phosphatase 1, regulatory (inhibitor) subunit 8 56204167 PPP1R8 Metabolism MCF7 39 98.03 2.1 ▴2.1
MDH2 49168580 MDH2 Metabolism MCF7 1183 100.0 0.490 ▾2.0
Triosephosphate isomerase 1 15929332 TPI1 Metabolism MCF7 1180 100.0 0.490 ▾2.0
Josephin MJD1 2262199 ATXN3 DNA repair T47D 83 99.99 0.493 ▾2.0
Actinin, alpha 4 12025678 ACTN4 Structural MDA 1805 100.0 0.497 ▾2.0
TPA: ubiquitin-specific protease 17-like protein 33186790 LOC401447 Ubiquitin cycle MCF7 39 98.16 2.0 ▴2.0
Ribonucleotide reductase M1 13676332 RRM1 DNA replication MCF7 39 98.13 2.0 ▴2.0
alpha1,6 Fucosyltransferase 7288173 FUT8 Metabolism MCF7 39 98.10 2.0 ▴2.0
Gene ontology information was derived from the GOA database (http://www.ebi.ac.uk/GOA/).
*Target selected for Western blot analysis (Figure 5; Table 5).
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the T47D and T47DRR cell lines revealed that proteasome alpha 1
subunit isoform 2 (PSMA1), proteasome subunit beta type 2 (PSMB2),
and 26S proteasome subunit p40.5 (PSMD13) were present in pa-
rental cells but were not detected in T47DRR cells, suggesting possible
down-regulation of these proteins in radioresistant cells. To analyze
this trend further, the expression of the 26S proteasome in all cell
lines was examined by Western blot analysis. The antibody used recog-
nized the 20S subcomplex within the 26S hetero-oligomeric protein
complex and also recognized the free cytosolic form of the 20S sub-
complex. A decrease in the expression of the 26S proteasome was
observed in all radioresistant derivatives in comparison with their par-
ents (Figure 6). Analysis revealed a decrease in expression by 7.7-fold,
45.1-fold, and 6.3-fold in MCF7RR, MDA-MB-231RR, and
T47DRR cells, respectively.
Immunohistochemistry was subsequently performed using this
same antibody to determine whether expression of the 26S proteasome
also correlated with response to radiotherapy in vivo. Pretreatment bi-
opsies were obtained for a series of patients diagnosed with early stage
laryngeal cancer. These patients were treated with single-modality ra-
diotherapy with curative intent, with documented radiosensitivity or
radioresistance, and therefore represented a suitable series with which
to determine whether expression of the 26S proteasome correlated
with radioresistance. Such a series is difficult to obtain for breast cancer
patients, where radiotherapy is used in the adjuvant setting, because of
a potentially large number of confounding variables. In total, 44 laryn-
geal squamous cell carcinomas were selected for a pilot analysis, clas-
sified into radiosensitive (n = 22) and radioresistant (n = 22) groups
matched as closely as possible to reduce the number of confounding
variables. Staining with the 26S proteasome, when evident, was pres-
ent in both the cytoplasm and the nuclei of tumor cells. In the radio-
resistant group, 18 (81%) of 22 tumors were negative for cytoplasmic
expression of the 26S proteasome. In contrast, only 12 (54%) of 22
radiosensitive tumors were negative. Loss of expression in the cyto-
plasm was associated with radioresistant tumors (P = .05) in this pilot
series (Figure 7).
Discussion
Radioresistance is a major problem in the effective management of
human cancers. We examined the inherent radiosensitivities of three
well-described breast cancer cell lines using a clonogenic survival assay
and revealed that each cell line differed in their response to radiother-
apy. The ER-positive, PR-positive (luminal subtype)MCF7, and T47D
cells were most sensitive to radiotherapy. Interestingly, the MDA-MB-
231 cells were the least sensitive. These cells have an ER-negative, PR-
negative, HER2-negative phenotype, which is representative of breast
cancers of the triple-negative molecular subtype. Triple-negative tumors
are more aggressive and have higher local recurrence rates after adjuvant
radiotherapy than that seen in luminal subtypes [13,14] and therefore
may benefit from a therapeutic strategy that involves radiosensitization.
Novel derivative cell sublines (MCF7RR, MDA-MB-231RR, and
T47DRR) were developed, which displayed significant resistance to
Table 5. Summary of Proteins Identified by 2DE-MS or iTRAQ, Grouped by Function, Where Additional Confirmation Was Provided by MS/MS from a Second Instrument, Western Blot (WB)
Analysis or Expression MA (eMA) with RT-qPCR (qPCR).
Protein Gene Name Known/Proposed Function Screening Method Confirmation (Fold Change)
Proteasome subunit, alpha type, 2 PSMA2 Protein degradation 2DE ▾ MS/MS
Proteasome subunit, alpha type 7 PSMA7 Protein degradation 2DE ▾ MS/MS
WB (▾18.3×)
Proteasome activator subunit 1, isoform 2 PSME1 Protein degradation 2DE ▾ qPCR (▾2.7×)
eMA ▾
Proteasome activator subunit 2 (PA28 beta) PSME2 Protein degradation 2DE ▾ qPCR (▾2.0×)
Heat shock 90-kDa protein 1 beta HSP90AB1 Protein folding/degradation 2DE ▴ MS/MS
WB (▴2.0×)
TRAP1 (HSP75) TRAP1 Protein folding/degradation 2DE ▴ MS/MS
WB (▴9.4×)
Ubiquitin-activating enzyme E1 UBA1 Ubiquitin cycle 2DE ▴ MS/MS
WB (▾2.8×)*
Aspartyl-tRNA synthetase (DARS) DARS Protein biosynthesis 2DE ▴ WB (▾4.2×)*
Aspartyl-tRNA synthetase (DARS) 2DE ▾ WB (▾12.4×)
Aspartyl-tRNA synthetase (DARS) — WB (▾11.4×)
Glutaminyl-tRNA synthetase† QARS Protein biosynthesis 2DE ▴ MS/MS
Eukaryotic translation initiation factor 4A, isoform 1 EIF4A1 Protein biosynthesis 2DE ▴ MS/MS
G elongation factor, mitochondrial 1 GFM1 Protein biosynthesis 2DE ▴ MS/MS
Glutathione S -transferase M3 GSTM3 Metabolism 2DE ▾ WB (▾15.7×)
eMA ▾ qPCR (▾3.8×)
Fructose-bisphosphate aldolase A ALDOA Metabolism 2DE ▴ WB (▴30.3×)
Triosephosphate isomerase 1‡ TPI1 Metabolism 2DE ▾ MS/MS
Triosephosphate isomerase 1 iTRAQ ▾ MS/MS
α-Tubulin TUBA1A Structural 2DE ▾ MS/MS
L-Plastin LCP1 Structural 2DE ▾ WB (▾69.9×)
Moesin MSN Structural 2DE ▾ WB (▾4.4×)
Glucose-regulated protein (GRP78) HSPA5 Regulation of apoptosis iTRAQ ▾3.3 MS/MS
WB (▾2.9×)
Glucose-regulated protein (GRP78) iTRAQ ▾2.0 MS/MS
WB (▾2.0×)
Source cell line is indicated by color (T47DRR, MCF7RR, and MDA-MB-231RR).
▾ indicates decreased expression in RR; ▴, increased expression in RR.
*Contradictory direction of expression change.
†WB attempted but expression change not confirmed.
‡WB attempted but antibody unreliable.
Neoplasia Vol. 11, No. 11, 2009 Proteomics in Radioresistance Smith et al. 1203
radiotherapy. These derivative cells were compared with parent cells to
identify putative biomarkers associated with the radioresistant pheno-
type. This area of breast cancer research has recently been highlighted
as a significant knowledge “gap” by the Breast Cancer Campaign [15].
In 2005, Wang et al. [16] established a radioresistant derivative from
MCF7 parent cells and used a global 2DE-MS proteomic approach to
reveal an up-regulation of peroxiredoxin II in radioresistant cells. The
silencing of peroxiredoxin II using small interfering RNA only partially
restored sensitivity to radiotherapy, suggesting that other factors are as-
sociated with response [16]. Our study is the first of its kind using a
range of complementary proteomic methods to analyze radioresistance
in breast cancer cells. We identified very few overlapping targets from
data produced by 2DE-MS, iTRAQ, and LC-MALDI MS/MS ap-
proaches, highlighting the importance of using a comprehensive, com-
plementary screening approach in biomarker discovery.
A summary of the putative protein biomarkers associated with radio-
resistance in this study, where some confirmatory evidence has been
obtained, is given in Table 5, and these proteins are discussed later. A
number of other interesting observations remain to be confirmed in-
cluding the independent identification of the down-regulation of fila-
min A alpha in two radioresistant cell lines by iTRAQ analysis and the
identification of a number of proteins from the heat shock protein fam-
ily, which exhibited down-regulation in MCF7-RR cells by iTRAQ
analysis (Table 4).
Proteins Identified from More than One RR Cell Line
DARS was identified by 2DE-MS in two of three radioresistant cell
lines (upregulated in T47DRR cells but downregulated in MDA-MB-
231RR cells). Western blot analysis revealed a significant decrease in
expression in all three radioresistant cell lines (Table 5). The reason for
the discrepancies between these techniques is unclear but highlights
the importance of independent data confirmation. DARS is involved
in protein biosynthesis and has no previous link to radioresistance.
Figure 4. Several targets identified by 2DE-MS from each pair of cell lines were selected for confirmation using Western blot analysis.
Each band was quantitated by densitometry using Quantity One software (Bio-Rad) and normalized to a GAPDH loading control. A
change in expression of at least two-fold was taken to be significant. Analysis revealed the down-regulation of DARS in all radioresistant
derivatives in comparison with the respective parent cells (MCF7RR, 11.4-fold decrease in expression; MDA-MB-231RR, 12.4-fold de-
crease; T47DRR, 4.2-fold decrease). The down-regulation of L-plastin (69.9-fold decrease) and GST-M3 (15.7-fold decrease) in MCF7RR
cells relative to parental MCF7 cells was confirmed. The down-regulation of keratin 17 reached only a 1.7-fold decrease in MCF7RR cells
relative to parental MCF7 cells. The down-regulation of PSMA7 (18.3-fold decrease) and Moesin (4.4-fold decrease) in MDA-MB-231RR
cells relative to parental MDA-MB-231 cells was confirmed. The up-regulation of HSP90 beta (2.0-fold increase), TRAP1 (9.4-fold in-
crease), and aldolase A (30.3-fold increase) was also confirmed. See Figure 3 for abbreviations. See Table 5 for summary.
Figure 5. After iTRAQ analysis, the down-regulation of glucose-
regulated protein (GRP78) in MCF7RR cells (2.9-fold decrease) and
MDA-MB-231RR cells (2.0-fold decrease) relative to their parents
(MCF7 and MDA-MB-231, respectively) was confirmed by Western
blot analysis. Each band was quantitated by densitometry using
Quantity One software (Bio-Rad) and normalized to a GAPDH load-
ing control.
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Glucose-regulated protein (GRP78) was identified by iTRAQ in
two of three radioresistant cell lines (downregulated in MCF7RR and
MDA-MB-231RR cells). Western blot analysis confirmed a significant
decrease in the expression of both of these radioresistant cell lines
(Table 5). Glucose-regulated protein is a molecular chaperone, and
overexpression has been associated with cell survival and chemoresis-
tance in a number of cancer types [17–19]. No association with radio-
resistance has been previously identified.
Proteins Identified by Both 2DE-MS and iTRAQ
The down-regulation of triosephosphate isomerase 1 (TPI1) was
identified in MCF7RR cells by iTRAQ and in MDA-MB-231RR
cells by 2DE-MS (Table 5). A reliable antibody against triosephosphate
isomerase 1 was not found, and therefore, Western blot analysis con-
firmation has not been possible.
Proteins Identified by Both iTRAQ and LC-MALDI
The expression of the structural maintenance of chromosomes 3
(SMC3) protein was found to be downregulated by a factor of 2.5-
fold in T47DRR cells compared with parental cells. This result is
supported by the LC-MALDI MS/MS results, which identified the
structural maintenance of chromosomes 3 protein in T47D cells but
not in T47DRR cells, which may suggest that this protein has been
downregulated. The structural maintenance of chromosomes 3 protein
is involved in a protein complex that detects and repairs DNA DSBs.
The 26S Proteasome
Our findings suggested that the down-regulation of the 26S pro-
teasome may be associated with radioresistant phenotype. The down-
regulation of PSMA2) and PSMA7 was identified by 2DE-MS/MS
analysis in the MDA-MB-231RR cells (Table 5). LC-MALDI-MS/
MS analysis of the T47DRR cells also provided some contributory
evidence, suggesting down-regulation of PSMA1 and PSMB2, as well
as down-regulation of the PA700/19S regulatory subunit (PSMD13;
Table 3). In a pilot immunohistochemical study of early laryngeal car-
cinomas, from patients treated preoperatively with radiotherapy, the
use of the 26S proteasome antibody demonstrated down-regulation
of this protein complex. This was significantly associated with the
radioresistant tumor subset in this pilot series (P = .05). This puta-
tive biomarker may represent a general predictive test for radiotherapy
outcome and therefore warrants further investigation in a larger series
of tumors.
The primary catalytic site of the 26S proteasome is a 20S core; a
barrel-shaped complex composed of rings of alpha and beta subunits
[20]. In isolation, the 20S Proteasome is inactive because substrates are
unable to access the active sites. Thus, the 26S proteasome requires
activation by the PA700/19S, which binds to both ends of the 20S
core to form the 26S proteasome. The 26S proteasome recognizes
and degrades proteins that have been modified by polyubiquitination.
The mechanisms of how the down-regulation of the 26S proteasome
may contribute to radioresistance remain unclear because this complex
is involved in the degradation of proteins from a wide variety of func-
tional pathways. Compromising the function of the 26S proteasome
Figure 6. Western blot analysis of the 26S proteasome in the three radioresistant derivatives in comparison with parental cell lines. Each
band was quantitated by densitometry using Quantity One software (Bio-Rad) and normalized to a GAPDH loading control. The 26S pro-
teasome antibody (ab21165; Abcam), which recognizes the 20S component of the 26S proteasome, produced the expected band size of
approximately 32 kDa. A significant decrease in the expression of the 26S proteasome was observed in all radioresistant derivatives in
comparison with parental cell lines: MCF7RR, 7.7-fold decrease; MDA-MB-231RR, 45.1-fold decrease; T47DRR, 6.3-fold decrease.
Figure 7. Immunohistochemistry to detect the 26S proteasome (Ab21165; Abcam) was performed using a pilot series of 44 biopsies
taken from early stage laryngeal tumors before treatment with primary radiotherapy. Loss of expression in the cytoplasm was signifi-
cantly associated with radioresistant tumors (P = .05). (a) Representative image of a tumor with positive cytoplasmic staining. (b) Tumor
lacking expression of the 26S proteasome.
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may result in the increased stability of those proteins required for the
development of resistance to radiotherapy. Key cell cycle regulators
(e.g., cyclins and cyclin-dependent kinase inhibitors) are major substrates
for proteasomal degradation. Thus, it is possible that the inefficient
degradation of these proteins will prevent cell cycle arrest in response
to radiotherapy-induced DNA damage. The turnover of antiapoptotic
proteins such as Mcl-1 and Bfl-1/A1 is also under the influence of the
26S proteasome [21,22]. Thus, defective proteasomal degradation may
result in the inappropriate stabilization of those proteins harboring cell
survival properties.
It has also been shown that the ubiquitin-proteasome system is
functionally linked with autophagy, a second major intracellular pro-
tein degradation system [23]. Autophagy is usually responsible for the
degradation of long-lived proteins and other cellular components, but
evidence suggests that this system also plays a compensatory role and is
activated by proteasome inhibition [24]. Furthermore, numerous stud-
ies have shown that the induction of autophagy is protective against
cell death [23–27] and inhibition of autophagy concurrent with irra-
diation has been shown to enhance cytotoxicity of radiotherapy in re-
sistant cancer cells [27]. This provides a possible mechanism by which
down-regulation of the 26S proteasome may result in radioresistance.
It is also known that interactions occur between the 26S protea-
some and major DNA repair pathways, including the base excision
repair and DNA DSB repair pathways [28–30]. The 26S proteasome
may degrade proteins involved in the DSB repair pathway [28], and
therefore, the abnormal down-regulation of the proteasome in radio-
resistant cells may facilitate an increased DNA rate of repair of the
damage induced by irradiation.
There is previous evidence to suggest that the inactivation or
down-regulation of the 26S proteasome may be associated with resis-
tance to anticancer therapy [31], and this phenotype has recently
been identified as a marker of cancer stem cells [32]. Functional stud-
ies using RNAi and/or pharmacological inhibitors are now required
to determine whether the down-regulation of the 26S proteasome is a
cause or consequence of radioresistance in our in vitro cell culture
models because this would be counterintuitive to the clinical use
of proteasome inhibitors (e.g., bortezomib) for the radiosensitization
of tumor cells to the cytotoxic effects of radiotherapy.
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